The challenges of psychopharmacological management of children with severe developmental disabilities.
Ivanov
Iliyan
I
Mount Sinai School of Medicine, New York, New York, USA.
Klein
Martha
M
Green
Wayne Hugo
WH
Coffey
Barbara
B
D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001321:Autistic Disorder / Q000150:complications / Q000188:drug therapy; D017028:Caregivers; D002648:Child; D002658:Developmental Disabilities / Q000188:drug therapy*; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy; D005260:Female; D005581:Foster Home Care; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007175:Impulsive Behavior / Q000188:drug therapy; D008609:Mental Status Schedule; D011581:Psychological Tests; D018967:Risperidone / Q000627:therapeutic use; D013226:Status Epilepticus / Q000188:drug therapy; D000077236:Topiramate; D014635:Valproic Acid / Q000008:administration & dosage / Q000627:therapeutic use
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D000077236:Topiramate; D005632:Fructose; D014635:Valproic Acid; D018967:Risperidone